Resumen de: WO2023042181A1

A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.

Resumen de: AU2021321535A1

The present disclosure relates to methods and compositions for treating or preventing a beta-coronavirus infection, or for inhibiting symptoms of a disease caused by a beta coronavirus infection in a subject, including SARS-CoV-2 and COVID-19. In various embodiments, the composition and methods involve a combination of a non-steroidal anti-inflammatory drug (NS AID) and ketotifen. In exemplary embodiments, naproxen and/or indomethacin are combined with ketotifen for therapy in a single unit dose or separate compositions, and the combination is surprisingly and unexpectedly effective to reduce SARS-CoV-2 viral load and treat COVID-19.

Resumen de: WO2023040835A1

Provided are an alpaca-derived nanobody combined with a SARS-CoV-2 RBD or an antigen-binding fragment thereof, and an application thereof. The nanobody may effectively inhibit SARS-CoV-2 pseudovirus infections, and may be used for the prevention, treatment and/or detection of SARS-CoV-2 infection.

Resumen de: WO2023040627A1

A fully human monoclonal antibody ZWD12 against SARS-CoV-2. The antibody is obtained by screening using a flow sorting-single cell PCR technology and has a unique CDR, and the antigen recognition epitope of the antibody is located in an RBD region of S1 protein. The EC50 of the antibody against the wild type of SARS-CoV-2 is 0.103 μg/mL, and the EC50 neutralizing the Beta strain is 0.069 μg/mL, and the EC50 neutralizing the Delta strain is 0.079 μg/mL, showing that ZWD12 has broad-spectrum neutralizing activity against the current major mutant strains.

Resumen de: WO2023040023A1

Disclosed is a mouth and nose mask having visually targeted collection of a novel coronavirus sample and a visual warning, belonging to the technical field of personal protection and pathogen sample collection. The mouth and nose mask comprises ear loops (3) as well as a mouth and nose mask body (1). An outermost layer of the mouth and nose mask (1) is an antifouling layer (7), an innermost layer is a skin-friendly layer (4), and a middle layer comprises a visible pathogen-targeted collection layer (5) or/and a filter layer (6). The visible pathogen-targeted collection layer (5) contains a color-changing material (8). The mouth and nose mask can visually target and collect saliva, droplet and aerosol-borne pathogens from suspected patients or patients with respiratory infectious diseases and also provides a warning function, thereby achieving the separation of the subject and the medical staff when collecting a novel coronavirus pathogen sample, reducing the risk of infection while increasing sample collection efficiency and reducing false negative rates.

Resumen de: WO2023040026A1

An immunochromatographic detection reagent strip and a kit comprising same, and applications of both, relating to the technical field of biological detection. According to the immunochromatographic detection reagent strip, fluorescent microspheres, latex, colloidal gold or colloidal carbon are coupled to a specific protein by using immunochromatography to obtain a specific protein complex. The specific protein comprises a novel coronavirus N protein first antibody, an influenza A virus NP protein first antibody and an influenza B virus NP protein first antibody, which are used to bind novel coronavirus N protein, influenza A virus NP protein and influenza B virus NP protein antigens. A nasopharyngeal swab, oropharyngeal swab, or saliva from a patient are then detected. The immunochromatographic detection reagent strip has the advantages of high sensitivity, high specificity and quantitative detection, and avoids weak positive sample missed detection and false positive sample false detection to the greatest extent.

Resumen de: WO2023040990A1

A new combination drug or a new pharmaceutical composition containing nitazoxanide and used with atovaquone and/or ribavirin, and the use thereof in preventing or treating coronavirus infections, in particular the use in preventing or treating infections caused by SARS-CoV-2 and mutants thereof.

Resumen de: WO2023040733A1

Disclosed in the present invention are a class of baicalein derivatives, and a preparation method therefor and the uses thereof. The structure of the baicalein derivative of the present invention is as represented by the following general formula (I). According to pharmacological experiment verification, the baicalein derivative of the present invention exhibits an inhibitory activity against novel coronavirus, and can be used as an anti-novel coronavirus drug or a potential drug for treating related diseases caused by the novel coronavirus.

Resumen de: AU2021286756A1

Present invention is a designation of a novel medicament for immune modulation and treating chronic or hyper inflammation. Its active ingredient is anabasine or its salt. It was designed for example to treat some of auto immune diseases permanently such as asthma and atopic dermatitis by one medication course, to stop the progression and development of diabetes type 2 in diabetics and restoring their blood sugar to normal with respect to administration in the disease early stages, to prevent the incidence and development of autoimmune Diabetes Type 1 resulted from T cell-mediated damage of pancreatic β-cells and loss of insulin production. Further, it plays a pivotal and protective role in treating hazardous infections caused by diverse pathogens to promote and accelerate recovery, including COVID -19 with its variants.

Resumen de: US2023092650A1

The present disclosure relates to immunogenic compositions comprising a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, and a toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide comprising an unmethylated cytidine-phospho-guano sine (CpG) motif. The immunogenic compositions are suitable for stimulating an immune response against a SARS-CoV-2 in an individual in need thereof.

Resumen de: AU2021360898A1

The present application describes chimeras which target and degrade essential viral proteins or host proteins involved in viral pathogenesis. In particular, the chimeras of this application combine a moiety that binds to a target protein (such as a coronaviral papain-like protease (PLpro), main protease (Mpro), or other non-structural proteins (e.g., NSP9 or NSP12); or a host protein, such as bromodomain 2, bromodomain 3, or bromodomain 4)), with a moiety that recruits a protein degrader, thereby degrading the target protein. In some instances, the chimera simultaneously induces p53, which itself has anti-viral activity, by engaging HDM2 as the protein degrader. The disclosure also relates to methods of using such chimeras in the prevention and treatment of viral infections, particularly viral infections (such as COVID-19) caused by coronaviruses (such as SARS-CoV-2).

Resumen de: AU2021316668A1

The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2, a strategy for an enhanced block of the homotrimeric viral spike proteins by symmetry-matching VHH-fusions, implementations of this strategy, as well as VHH antibodies for sensitive detection of SARS-CoV2-infections.

Resumen de: AU2021315818A1

The present disclosure relates to fusion protein compositions and methods of reducing and treating viral infections. The fusion proteins include a polypeptide comprising a bl domain, or a derivative or fragment thereof, of a neuropilin; an ACE2 domain, or a derivative or a fragment thereof, of an angiotensin converting enzyme 2; and or an immunoglobulin domain. Both the bl and ACE2 domains are capable of binding to a coat protein of a virus selected from the group consisting of herpesviridae, papillomaviridae, coronaviridae, flaviviridae, togaviridae, bomaviridae, bunyaviridae, filoviridae, orthomyxoviridae, paramyxoviridae, pneumoviridae, and retro viridae. In some embodiments, the bl domain, or a derivative or fragment thereof, and/or the (ACE2) domain, can be used to specifically bind S proteins of COVID-19 particles.

Resumen de: WO2023041985A2

The invention provides nanobodies that bind with high affinity to SARS-CoV- 2 non-structural protein (Nsp), as well and compositions comprising the identified nanobodies and methods of use thereof to block activation of SARS-CoV-2 viral replication, and for the treatment or prevention of COVID-19.

Resumen de: WO2023044272A1

Methods for producing synthetic single-domain monoclonal antibody libraries using humanized llama nanobody framework sequences, libraries obtainable by the method, as well as antibodies selected from the libraries are described. In particular, synthetic single-domain monoclonal antibodies that specifically bind to the spike protein of SARS-CoV-2 and neutralize SARS-CoV-2 infection are described. Use of the disclosed antibodies for the detection, prophylaxis and treatment of SARS-CoV-2 infection is described.

Resumen de: WO2023041564A1

The invention relates to novel primers, probes, kits and methods for determining the presence or absence of SARS-CoV-2.

Resumen de: WO2023041808A1

A molecularly imprinted polymer comprises at least one recognition site that is complementary to a template molecule consisting of an amino acid sequence corresponding to a subsequence of the receptor binding domain of SARS-CoV-2 spike protein, wherein the amino acid sequence is no more than 50 amino acids in length and comprises a sequence selected from (i) NSNNLDSKVGG, (ii) NYNYLYRLFRKS, (iii) YRLFRKSNLKPF, (iv) STEIYQAGSTPC, (v) CNGVEGFNCYF,(vi) GSTPCNGVEGF, (vii) CYFPLQSYGFQP, (viii) GFQPTNGVGYQ and (ix) LQSYGFQPTNG. A method of preparing the molecularly imprinted polymer is also provided. Conjugates comprising the molecularly imprinted polymer and a fluorophore are also provided as are compositions containing the molecularly imprinted polymer and conjugates of the invention. The molecularly imprinted polymer, conjugate and compositions can be used in the detection of SARS-CoV-2.

Resumen de: US2023089695A1

Live attenuated viruses for protection against the novel coronavirus, designated as Sars-CoV-2 by the World Health Organization (WHO) are provided. The live attenuated chimeric virus strains are based on a live attenuated influenza B virus (LAIVB), used a master backbone, which includes deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1-B), engineered to express one or more antigens of the Sars-CoV-2 (herein, CoV2Ag). The chimeric virus strain is referred to generally herein, as DelNS1-B-Sars-CoV-2-CoV2Ag. The DelNS1-B-Sars-CoV-2-CoV2Ag strain preferably shows spontaneous cold adaption with preference to grow at 30-33° C. The DelNS1-B-Sars-CoV-2-CoV2Ag strain can be used to protect a subject in need thereof, against a challenge of Sars-CoV-2. DelNS1-B-Sars-CoV-2-CoV2Ag is an important strategy for making highly attenuated and immunogenic live attenuated vaccines with the ability to induce protective immunity against Sars-CoV-2.

Resumen de: US2023087388A1

The present application relates to small molecule inhibitors of human deubiquitinases for use in the prevention or treatment of a coronaviral infection. It relates in particular to small molecule inhibitors of USP7 and USP47. Pharmaceutical compositions, respective advantageous formulation techniques and a method of treatment are disclosed.

Resumen de: US2023086390A1

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

Resumen de: US2023089605A1

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to a therapeutic treatment or prevention of viral infections such as, for example, COVID-19. In one aspect, the therapeutic treatment combines the administration of doxycycline and/or chemically-modified tetracyclines with resveratrol and ivermectin. In another aspect, the disclosed treatment offers anti-inflammatory effects, can combat the effects of reactive oxygen species, and can inhibit the activity of matrix metalloproteinase enzymes; these combined effects may, in some aspects, be useful in preventing or mediating the effects of the cytokine storm that is associated with poor COVID-19 outcomes including death. In some aspects, dosages of the treatment can be modified to account for COVID-19 comorbidities including, but not limited to, such conditions as diabetes or hypertension.

Resumen de: US2023087473A1

A suspo-emulsion dosage form of anthelmintic drug such as Ivermectin or niclosamide with essential oils was proposed to be used for administration to the nasal cavity and lungs. The suspo-emulsion formulation is to be administered using a suitable medical device. The composition may be used to treat or prevent viral infections such as Covid-19.

Resumen de: US2023090517A1

A composite quaternary ammonium salt disinfectant includes a double long-chain quaternary ammonium salt, two single long-chain quaternary ammonium salts, a synergist isothiazolinone, a nonionic surfactant fatty alcohol polyvinyl ether, and water, wherein the double long-chain quaternary ammonium salt is dialkyl dimethyl ammonium chloride with dialkyl being two independent alkyl groups with a chain length of C8-C18, and the two single-chain quaternary ammonium salts are alkyl dimethyl benzyl ammonium chloride with an alkyl chain length of C8-C18 and alkyl dimethyl ethyl benzyl ammonium chloride with an alkyl chain length of C8-C18, respectively. The composite quaternary ammonium salt disinfectant has a synergistic effect among its components, which greatly improves the capacity of resisting interferences by hard water and organics; and can kill not only bacterial propagules, lipophilic viruses (enveloped viruses, such as novel coronavirus) and fungi, but also hydrophilic viruses (non-enveloped viruses).

Resumen de: US2023090502A1

The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.

Resumen de: US2023091497A1

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.